linjc16/ctgov huggingface dataset:
Conversations You Want About Corona Virus Disease (COVID-19)

Study Overview
=================
Brief Summary
-----------------
Web-enabled virtual topical guide: develop virtual conversations for each concern and intensity level

Detailed Description
-----------------
Study will pilot test the virtual topical discussion guide with diverse health care professions and community members to confirm it is clear, relevant, understandable, and culturally appropriate

Official Title
-----------------
BECAUSE YOU MATTER: Conversations You Want About COVID-19

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: greater than or equal to 18 years of age English or Spanish speaking only Exclusion Criteria: less than 18 years of age not English or Spanish speaking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Virtual topical discussion guide<br>Study will pilot test this virtual topical discussion guide to assess feasibility and acceptability by diverse patient populations. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time spent with the guide | Time spent with the guide | Week 4 | 
| Number of clinics viewed in the guide | Number of clinics viewed in the guide | Week 4 | 
| Number of content areas accessed | Number of content areas accessed | Week 4 | 
| Time spent with each content area | Time spent with each content area | Week 4 | 
| Helpfulness of Tool | How helpful was this tool in your decision-making, ranging from 1 not at all helpful to 5 incredibly helpful | Week 4 | 
| Number of Subjects saving responses | Individuals will have the ability to send their guide responses to themselves for later use | Week 4 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vaccines
Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy

Study Overview
=================
Brief Summary
-----------------
Grass pollen and house dust mites (HDM) are the most common allergens causing allergic rhino-conjunctivitis (RC) and/or asthma (A). Subcutaneous allergen specific immunotherapy (SCIT) reduces symptoms and use of medication. The purpose of SABAL is to assess the effect of SCIT on disease severity classifications in terms of number of days affected- and sick days on patients with grass pollen and/or HDM induced disease. These outcome measures will be gathered in one single measure: Quality Adjusted Life Years (QALY)

Official Title
-----------------
Health Economic Analyses of Treatment Strategies for Allergic Respiratory Diseases

Conditions
-----------------
Hypersensitivity, Asthma, Rhino-Conjunctivitis, Quality of Life, Effects of Immunotherapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults (> 16 years) and allergic to grass pollen and/or house dust mites. Exclusion Criteria: Allergic patients who had been immunotherapy treated before.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger

Study Overview
=================
Brief Summary
-----------------
Aim: The purpose of the study is to learn more about how a person recovers after treatment for mallet finger injury. The investigators want to identify the best outcome after mallet finger injury and how to improve treatment strategies. Primary null hypothesis: There are no statistically significant factors associated with extensor lag between 4 weeks and 4 months after immobilization is discontinued for a mallet finger among demographic, injury, and treatment factors. Secondary null hypothesis: There are no statistically significant factors associated with PROMIS upper extremity function between 4 weeks and 4 months after completion of immobilization for a mallet finger among demographic, psychological, injury, and treatment factors.

Official Title
-----------------
Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger

Conditions
-----------------
Patients Present With Mallet Finger

Intervention / Treatment
-----------------
* Other: PROMIS Upper Extremity
* Other: Likert Pain Scale
* Other: Mallet Finger Extensor Lag Measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age and older English fluency and literacy Mallet finger fracture or non-fracture Mallet finger subluxation or non-subluxation Exclusion Criteria: Pregnant Women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with Mallet Finger<br>All enrolled patients | Other: PROMIS Upper Extremity<br> <br> Other: Likert Pain Scale<br> <br> Other: Mallet Finger Extensor Lag Measurement<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mallet Finger Extensor Lag |  | Baseline | 
| Mallet Finger Extensor Lag |  | 4 weeks to 4 months after diagnosis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Reported Outcomes Measure Information System (PROMIS) Upper Extremity | A computerized assessment of upper extremity function | 4 weeks to 4 months after diagnosis | 
| Likert Pain Scale |  | 4 weeks to 4 months after diagnosis | 
| Demographics Questionnaire |  | 4 weeks to 4 months after diagnosis |
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as add-on to current Oral Antidiabetic Drug treatment in reducing HbA1c in patients with Type 2 Diabetes.

Official Title
-----------------
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine as Add-on to Current Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin detemir
* Drug: insulin glargine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 Diabetes for more than 12 months, and no previous insulin treatment Oral Antidiabetic Drug treatment for at least 4 months Body Mass Index (BMI) less than 40 kg/m2 HbA1c 7.5-10.0% Exclusion Criteria: Current or previous treatment with thiazolidinediones within the last 6 months Oral Antidiabetic Drug treatment with combination of three or more Oral Antidiabetic Drugs within the last 6 months Proliferative retinopathy or maculopathy Known hypoglycaemia unawareness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: insulin detemir|nan|
|Drug: insulin glargine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | after 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin antibodies |  |  | 
| Incident of hypoglycaemic episodes and adverse events |  |  | 
| Plasma glucose profiles |  |  | 
| Change in body weight |  |  |
The Role of Serum Anticholinergic Activity in ACVB Patients

Study Overview
=================
Brief Summary
-----------------
Drugs with anticholinergic potential increase the risk of postoperative transient and persistent cognitive dysfunction especially in cardiac patients. The investigators main goal is to identify preoperative risk factors and to monitor postoperative patients' state in relation to SAA activity and bilateral BIS-EEG changes.

Official Title
-----------------
Serum Anticholinergic Activity (SAA) and BIS-EEG as Potential Markers for Cognitive Ability and/or the Anticholinergic Medication in ACVB Patients

Conditions
-----------------
BIS-EEG, Acetylcholine, Cognition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: written compliance to the study participation a good knowledge in German speech no red/ green blindness no previous neurological and/or psychiatric illness good ability to see and to hear Mini-Mental-State-Examination (MMSE) better than 25 points Exclusion Criteria: no written compliance to the study participation bad knowledge in German speech red/ green blindness previous neurological and/or psychiatric illness no ability to see and to hear Mini-Mental-State-Examination (MMSE) lower than 25 points

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| low SAA<br> | |
| high SAA<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive dysfunction measured by neurocognitive test battery |  | 3 month postsurgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SAA, BIS-EEG, descriptive patients' characteristics |  | 24 h postsurgery |
Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) (18FDG-PET)

Study Overview
=================
Brief Summary
-----------------
Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis.Resistin was shown to induce vascular endothelial dysfunction and vascular smooth muscle cell proliferation. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.Therefore, the purpose of the study is to demonstrate the correlation between circulating resistin and vascular inflammation detected by 18FDG-PET in obese persons.

Official Title
-----------------
Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18FDG-PET in Obese Person

Conditions
-----------------
Atherosclerosis

Intervention / Treatment
-----------------
* Other: Cross sectional study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers for visiting routine medical check in our clinic Exclusion Criteria: History of cardiovascular disease (myocardial infarction, unstable angina,stroke, or cardiovascular revascularization) Diabetes Hypertension Malignancy Severe renal or hepatic disease Subjects taking medications that might affect inflammation such as non-steroidal anti-inflammatory drugs (NSAIDs) and statin

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obese Group<br> | Other: Cross sectional study<br>* This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting<br>|
| Non Obese Group<br> | Other: Cross sectional study<br>* This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vascular inflammation in carotid arterial wall represented as the target-to-background ratio (TBR) using FDG-PET |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circulating serum adiponectin levels |  | 12 weeks | 
| carotid intima-media thickness levels measured using ultrasonography |  | 12 weeks | 
| Circulating serum resistin levels |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atherosclerosis, vascular inflammation, resistin, adiponectin, 18FDG-PET
Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection

Study Overview
=================
Brief Summary
-----------------
We explores the accuracy and sensitivity of rapid intraoperative detection of IDH, TERT, BRAF indicators through a prospective clinical multi-center study. This part includes a total of 300 fresh tissue samples, paired blood samples, relevant clinical information and follow-up information from 300 patients with different grades of adult glioma. By comparing with the postoperative sequencing results, the specificity and sensitivity of intraoperative IDH and TERT rapid detection results are clear.

Official Title
-----------------
Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection

Conditions
-----------------
Glioma, Malignant

Intervention / Treatment
-----------------
* Diagnostic Test: Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Glioma patients with Informed Consent Form 2. Glioma patients with intact clinical information Exclusion Criteria: 1. Glioma patients without Informed Consent Form 2. Glioma patients without intact clinical information

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e |  | Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e |
Oligodendrocyte Progenitor Cell Culture From Human Brain

Study Overview
=================
Brief Summary
-----------------
Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.

Detailed Description
-----------------
Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.

Official Title
-----------------
Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain

Conditions
-----------------
Demyelinating Diseases

Intervention / Treatment
-----------------
* Procedure: Oligodendrocyte progenitor cell culture/craniotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female 20-65 years of age Informed consent Has elective craniotomy surgery Exclusion Criteria: HIV, hepatitis, and other central nervous system (CNS) infections Dementia, Alzheimer disease, and neurodegenerative disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Interventional Model Description: Cell culture
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured. | Procedure: Oligodendrocyte progenitor cell culture/craniotomy<br>* Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply<br>* Other names: Rajavithi Oligodendrocyte progenitor cell culture protocol;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of oligodendrocyte progenitor cell differentiation |  | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
All selective craniotomy
Clinical and Radiological Investigation of a New Spinal Fixateur Interne (Ennovate®)

Study Overview
=================
Brief Summary
-----------------
This study is planned and conducted to document all patients in the participating Centers, who are treated with the CE-marked product, the Fixateur Ennovate®, regardless of the diagnosis or indication. Data on performance and safety of the product, validated patient based questionnaires (Oswestry Disability Index, ODI) as well as the satisfaction of the patients in general are captured.

Detailed Description
-----------------
The list of spinal treatments is growing, and healthcare authorities today are at times limiting their access due to a lack of evidence of safety and efficiency. The study enables a quick, but detailed implant documentation, which is of great interest for the current and future users of the internal fixation system targeted in this study. It includes the relevant outcomes to evaluate safety and efficacy of the implant system for various indications in trauma and degenerative disorders.

Official Title
-----------------
Total Indications Ennovate® Non-Interventional Study on Clinical and Radiological Results With Pedicle Screw Fixation

Conditions
-----------------
Spinal Fusion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Consent in the documentation of clinical and radiological results Exclusion Criteria: - If it is clear that the patient cannot participate in a follow-up examination, he will be excluded from the study documentation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Clinical Results from Preoperative Status to Follow-Up at 12 Months | Clinical Results measured by Oswestry Disability Index (ODI). ODI contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel, each topic category is followed by 6 statements describing different potential scenarios in the patient's life relating to the topic. Each question is scored on a scale of 0 (indicating the least amount of disability) to 5 5 (indicating most severe disability). The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible. | preoperative, 12 months postoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spinal Fusion
CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

Study Overview
=================
Brief Summary
-----------------
This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.

Official Title
-----------------
The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma

Conditions
-----------------
Glioblastoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chinese nationality No limits on Gender and age First diagnosed GBM Brain tumor tissue cytological diagnosis of glioblastoma (GBM, pleomorphic glioblastoma, WHO level IV) Exclusion Criteria: Other types of glioma by histological diagnosis Tumor tissue not eligible for the central laboratory testing standard No enough tumor tissue for the central laboratory test
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CD95 Ligand Positive Rate |  | 0 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CpG2 Positive Rate |  | 0 day |